Daewoong Pharma reports 104 patients enrolled in Phase 2 IPF trial of Bersiporocin

Daewoong Pharma presented baseline data for 104 patients in a global Phase 2 trial of IPF candidate bersiporocin at ERS 2026. The study is designed to test the drug in patients already on standard antifibrotic therapy, as well as those not receiving it. Enrollment is complete in the US and South Korea, positioning the program for a key efficacy and safety readout. Top-line Phase 2 results are expected in H1 2027, a near-term catalyst for the asset’s next-stage development plans. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daewoong Pharma published the original content used to generate this news brief via (Ref. ID: EN54703) on September 24, 2026, and is solely responsible for the information contained therein. (C)